Grants and Contributions:
Title:
Proof of concept of new drug therapy for Cystic Fibrosis
Agreement Number:
924681
Agreement Value:
$50,000.00
Agreement Date:
Feb 15, 2019 - Jan 31, 2020
Description:
SolAeroMed Inc is developing respiratory based technologies spun out of the University of Calgary. The project will support a proof of concept study to evaluate the firm's lead drug S1226 in Cystic Fibrosis (CF).
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Calgary, Alberta, CA T3E 6L1
Reference Number:
172-2018-2019-Q4-924681
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
829682111
Recipient Type:
For-profit organization
Recipient's Legal Name:
SolAeroMed Inc.
Federal Riding Name:
Calgary Centre
Federal Riding Number:
48004
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410